retatrutide phase 2 nejm weight loss 48 weeks percent study sees significant in obesity drug study retatrutide phase 2 nejm weight

Who Should Not Use GLP-1 Medications According to standard clinical guidelines and prescribing information, GLP-1 medications may not be appropriate for individuals who: Have a personal or family history of medullary thyroid carcinoma Have multiple endocrine neoplasia syndrome type 2 Have a history of pancreatitis Have severe gastrointestinal disease (gastroparesis, inflammatory bowel disease) Are pregnant, planning to become pregnant, or breastfeeding Have a history of severe allergic reactions to semaglutide, tirzepatide, or any inactive ingredients This is not a replacement for prescribed medical treatment for any health condition

While the concentration of active peptides in shampoo formulations is typically lower than in dedicated serums, daily use provides consistent exposure and can complement other interventions

That gap between hype and regulation is exactly where the biggest risk lies

effectiveness depends on consistent dosing and adherence

BPC-157's local effects are strongest near the injection site